Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Altimmune, Inc. reported revenue of $0M, up 105.0% year over year. Operating margin was -230461.0% and net margin -214861.0%, on a free-cash-flow margin of -164746.3% with capital expenditure at 26.8% of revenue. Every figure is computed directly from ALT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -230461.0% | -214861.0% |
| FY2024 | $0M | -515860.0% | -475295.0% |
| FY2023 | $0M | -22518.5% | -20762.2% |
| FY2022 | $-0M | 129029.4% | 124577.9% |
| FY2021 | $4M | -2197.4% | -2201.4% |
How does ALT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.